The 85%+ hsCRP reduction is a strong biomarker signal for cardiovascular benefit, potentially positioning BGE-102 as a best-in-class NLRP3 inhibitor. With Phase 2 data expected by end-2026, traders should monitor trial initiation and enrollment trends as near-term catalysts. The lack of serious safety signals supports further development across multiple indications, increasing the asset's optionality.
Price Chart
Executive Summary
BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsCRP and other inflammatory biomarkers in obese participants with elevated inflammation. The company plans to initiate Phase 2 proof-of-concept trials in cardiovascular risk and diabetic macular edema by mid-2026, with data expected by end-2026 and mid-2027, respectively.
Key Facts
- BGE-102 achieved 85% median hsCRP reduction at 60 mg dose and 86% at 120 mg dose in participants with obesity and elevated inflammation
- 87% of participants on 60 mg dose achieved normalized hsCRP (<2 mg/L) by Day 21
- Drug was well tolerated with no serious adverse events or discontinuations
- Phase 2 cardiovascular risk trial planned for initiation in first half of 2026, with data by end of year
- Phase 1b/2a trial in diabetic macular edema to start mid-2026, data expected mid-2027
Financial Impact
Non-dilutive near-term catalyst with potential to revalue the stock based on upcoming clinical data readouts in 2026–2027
Risk Factors
- Phase 1 biomarker improvements may not translate into clinical outcomes in larger trials
- Competition from other NLRP3 inhibitors in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 15w ago | Press Release | $20.49 $8.65 | ▼ −57.78% | ▼ −58.78% | $6.72 (−67.20%) |
May 8, 2026 21w ago | 8-K | $17.99 $11.20 | ▼ −37.74% | ▼ −42.58% | $6.72 (−62.65%) |
Apr 21, 2026 23w ago | DEFA14A | $18.36 $22.81 | ▲ +24.24% | ▲ +19.46% | $6.72 (−63.40%) |
Apr 21, 2026 23w ago | Press Release | $19.61 $22.16 | ▲ +13.00% | ▲ +6.10% | $6.72 (−65.73%) |
Apr 1, 2026 26w ago | 144 | $17.73 $24.95 | ▲ +40.72% | ▲ +27.34% | $6.72 (−62.10%) |
Mar 24, 2026 27w ago | Press Release | $16.11 $20.77 | ▲ +28.93% | ▲ +14.60% | $6.72 (−58.29%) |
Mar 2, 2026 30w ago | Court Ruling | $21.71 $16.95 | ▼ −21.93% | ▼ −31.26% | $6.72 (−69.05%) |
Feb 28, 2026 30w ago | Institutional Cluster | $21.71 $16.20 | ▼ −25.38% | ▼ −34.71% | $6.72 (−69.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access